Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Abiomed
Abiomed Receives FDA 510k Clearance for Impellaź 5.0 and Impellaź LD
May 15th, 2009
Abiomed, Inc. (NASDAQ: ABMD), a leading provider of break-through heart support technologies enabling safer revascularization, heart recovery and cost-effective patient care, announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Impellaź 5.0 and Impellaź LD Circulatory Support Devices. This 510(k) clearance designates Impella 5.0 and Impella LD to provide circulatory support for periods of up to six hours. Similar to the Impella 2.5, which received 510(k) clearance on June 2, 2008 for partial circulatory support for periods of up to six hours, the Impella 5.0 and Impella LD devices are minimally invasive catheter-based...
Source: Health Business Week (2009-05-15)
|
